BG63070B1 - Лекарствени форми на рисперидон във воден разтвор - Google Patents

Лекарствени форми на рисперидон във воден разтвор Download PDF

Info

Publication number
BG63070B1
BG63070B1 BG101106A BG10110697A BG63070B1 BG 63070 B1 BG63070 B1 BG 63070B1 BG 101106 A BG101106 A BG 101106A BG 10110697 A BG10110697 A BG 10110697A BG 63070 B1 BG63070 B1 BG 63070B1
Authority
BG
Bulgaria
Prior art keywords
solution
risperidone
range
solution according
water
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
BG101106A
Other languages
Bulgarian (bg)
English (en)
Other versions
BG101106A (en
Inventor
Marc Karel Francois
Willy DRIES
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26955530&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BG63070(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of BG101106A publication Critical patent/BG101106A/xx
Publication of BG63070B1 publication Critical patent/BG63070B1/bg
Anticipated expiration legal-status Critical
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BG101106A 1994-07-11 1997-01-04 Лекарствени форми на рисперидон във воден разтвор Active BG63070B1 (bg)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/272,462 US5453425A (en) 1994-07-11 1994-07-11 Risperidone oral formulation
US08/429,435 US5616587A (en) 1994-07-11 1995-04-26 Aqueous risperidone formulations
PCT/EP1995/002615 WO1996001652A1 (en) 1994-07-11 1995-07-04 Aqueous risperidone formulations

Publications (2)

Publication Number Publication Date
BG101106A BG101106A (en) 1997-08-29
BG63070B1 true BG63070B1 (bg) 2001-03-30

Family

ID=26955530

Family Applications (1)

Application Number Title Priority Date Filing Date
BG101106A Active BG63070B1 (bg) 1994-07-11 1997-01-04 Лекарствени форми на рисперидон във воден разтвор

Country Status (37)

Country Link
US (3) US5453425A (es)
EP (1) EP0769965B1 (es)
JP (1) JP2872412B2 (es)
KR (1) KR100212942B1 (es)
CN (1) CN1148226C (es)
AP (1) AP774A (es)
AT (1) ATE206931T1 (es)
AU (1) AU684193B2 (es)
BG (1) BG63070B1 (es)
BR (1) BR9508253A (es)
CA (1) CA2194564C (es)
CY (1) CY2268B1 (es)
CZ (1) CZ285204B6 (es)
DE (1) DE69523313T2 (es)
DK (1) DK0769965T3 (es)
EE (1) EE03426B1 (es)
ES (1) ES2165918T3 (es)
FI (1) FI116510B (es)
HK (1) HK1010691A1 (es)
HR (1) HRP950397B1 (es)
HU (1) HU222352B1 (es)
IL (1) IL114525A (es)
MX (1) MX9700374A (es)
MY (1) MY114389A (es)
NO (1) NO320366B1 (es)
NZ (1) NZ289432A (es)
PH (1) PH31626A (es)
PL (1) PL179972B1 (es)
PT (1) PT769965E (es)
RO (1) RO116778B1 (es)
RU (1) RU2161965C2 (es)
SI (1) SI9500220B (es)
SK (1) SK282159B6 (es)
TR (1) TR199500778A1 (es)
TW (1) TW420615B (es)
WO (1) WO1996001652A1 (es)
ZA (1) ZA955720B (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3645906B2 (ja) * 1993-11-19 2005-05-11 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ マイクロカプセル封入された３−ピペリジニル−置換１，２−ベンズイソオキサゾール類及び１，２−ベンズイソチアゾール類
US5453425A (en) * 1994-07-11 1995-09-26 Janssen Pharmaceutica N.V. Risperidone oral formulation
UA72189C2 (uk) 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
US6682758B1 (en) 1998-12-22 2004-01-27 The United States Of America As Represented By The Department Of Health And Human Services Water-insoluble drug delivery system
US6495164B1 (en) * 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
US20050232995A1 (en) 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
WO2004017975A1 (en) * 2002-08-23 2004-03-04 Ranbaxy Laboratories Limited Stable aqueous solutions of risperidone and methods for their preparation
EP1615924A1 (en) * 2003-04-22 2006-01-18 Synthon B.V. Water soluble salts of risperidone
AR044852A1 (es) 2003-06-24 2005-10-05 Novartis Ag Una composicion farmaceutica para la administracion parenteral que comprende un analogo de somatostatina
US20050036977A1 (en) * 2003-08-11 2005-02-17 Dilip Gole Taste-masked resinate and preparation thereof
ES2245252B1 (es) * 2004-06-15 2007-03-01 Farmalider, S.A. Solucion acuosa de risperidona para administracion oral.
ES2245891B1 (es) * 2004-07-09 2006-11-16 Clinmet S.L. "metodo para la obtencion de un excipiente universal para la administracion oral de principios activos farmaceuticos y composiciones de excipientes resultantes del metodo".
WO2006129160A2 (en) * 2005-06-01 2006-12-07 Aurobindo Pharma Limited Stable aqueous oral solution of risperidone
ATE424399T1 (de) * 2005-06-29 2009-03-15 Verisfield Uk Ltd Pharmazeutische zusammensetzungen von risperidon in wässriger lösung
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
JP4922657B2 (ja) * 2006-05-09 2012-04-25 高田製薬株式会社 リスペリドン経口用液剤
WO2007138462A2 (en) * 2006-06-01 2007-12-06 Wockhardt Ltd Aqueous oral formulations of risperidone
NZ581862A (en) 2007-05-25 2012-06-29 Tolmar Therapeutics Inc Injectable subcutaneous formulation comprising risperidone capable of forming a solid, microporous implant in a patient
US7776866B2 (en) * 2007-09-15 2010-08-17 Protia, Llc Deuterium-enriched risperidone
SI2234617T1 (sl) * 2007-12-19 2021-07-30 Janssen Pharmaceutica Nv Režim odmerjanja v zvezi z dolgodelujočimi paliperidonijevimi estri za injiciranje
EP3006024B1 (en) 2009-01-20 2019-03-20 Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center Benzoic acid or salts thereof to enhance the activity of a neuropharmaceutical
GB2513060B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
WO2013055386A2 (en) * 2011-10-03 2013-04-18 The University Of Utah Research Foundation Application of 5-ht6 receptor antagonists for the alleviation of cognitive deficits of down syndrome
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
DK3215223T3 (da) 2014-11-07 2020-08-03 Indivior Uk Ltd Buprenorphindoseringsskemaer
CA3027297A1 (en) 2016-06-13 2017-12-21 Syneurx International (Taiwan) Corp. Co-crystals of sodium benzoate and uses thereof
RU2022101542A (ru) 2016-06-13 2022-02-03 Сайньюрекс Интернэшнл (Тайвань) Корп. Сокристаллы бензоата лития и их применения
AU2017331340B2 (en) * 2016-09-23 2023-09-28 Delpor, Inc. Compositions for small molecule therapeutic agent compounds
US11369579B2 (en) 2016-10-24 2022-06-28 Syneurx International (Taiwan) Corp. Polymorphic forms of sodium benzoate and uses thereof
RU2646812C1 (ru) * 2016-10-24 2018-03-07 Общество с ограниченной ответственностью "Трейдсервис" Жидкая лекарственная форма рисперидона и способ ее получения
US10336679B2 (en) 2016-10-24 2019-07-02 Syneurx International (Taiwan) Corp. Polymorphic forms of sodium benzoate and uses thereof
US10646484B2 (en) 2017-06-16 2020-05-12 Indivior Uk Limited Methods to treat opioid use disorder
CN107260662A (zh) * 2017-06-21 2017-10-20 南京正科医药股份有限公司 一种利培酮口服溶液及其制备方法
CN107441037A (zh) * 2017-08-16 2017-12-08 南京正科医药股份有限公司 一种利培酮口服溶液
CN109589304A (zh) * 2017-10-01 2019-04-09 万特制药(海南)有限公司 利培酮口服溶液及其制备方法
US10098861B1 (en) 2017-10-24 2018-10-16 Syneurx International (Taiwan) Corp. Pharmaceutical composition comprising sodium benzoate compound and clozapine, and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4337261A (en) * 1980-07-28 1982-06-29 Hoechst-Roussel Pharmaceuticals Inc. (1,2-Benzisoxazol)phenoxyacetic acids as diuretics
IL88233A (en) * 1987-11-03 1993-08-18 Genentech Inc Gamma interferon formulation
FR2641278B1 (fr) * 1989-01-05 1991-03-22 Lipha Piperidines, procedes de preparation et medicaments les contenant
DK203990D0 (da) * 1990-08-24 1990-08-24 Novo Nordisk As Piperazinylderivater
TW376319B (en) * 1993-04-28 1999-12-11 Janssen Pharmaceutica Nv Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine
US5453425A (en) * 1994-07-11 1995-09-26 Janssen Pharmaceutica N.V. Risperidone oral formulation
FR2796273B1 (fr) * 1999-07-15 2003-09-12 Oreal Composition a phase grasse liquide gelifiee par un polyamide a groupements ester terminaux

Also Published As

Publication number Publication date
WO1996001652A1 (en) 1996-01-25
CZ2797A3 (en) 1997-07-16
HRP950397B1 (en) 2002-04-30
USRE39181E1 (en) 2006-07-11
FI116510B (fi) 2005-12-15
PH31626A (en) 1999-01-12
NO970051L (no) 1997-01-07
BG101106A (en) 1997-08-29
ES2165918T3 (es) 2002-04-01
RO116778B1 (ro) 2001-06-29
CN1148226C (zh) 2004-05-05
DK0769965T3 (da) 2002-02-04
SI9500220B (sl) 2004-12-31
AP9700910A0 (en) 1997-01-31
PT769965E (pt) 2002-04-29
DE69523313D1 (de) 2001-11-22
PL318132A1 (en) 1997-05-12
TW420615B (en) 2001-02-01
EP0769965A1 (en) 1997-05-02
EP0769965B1 (en) 2001-10-17
JP2872412B2 (ja) 1999-03-17
HUT76826A (en) 1997-11-28
EE03426B1 (et) 2001-06-15
SK2297A3 (en) 1997-09-10
DE69523313T2 (de) 2002-06-27
NO320366B1 (no) 2005-11-28
AU684193B2 (en) 1997-12-04
ZA955720B (en) 1997-01-10
US5616587A (en) 1997-04-01
FI970109A0 (fi) 1997-01-10
CY2268B1 (en) 2003-07-04
FI970109A (fi) 1997-01-10
AP774A (en) 1999-10-28
CN1155247A (zh) 1997-07-23
IL114525A (en) 1999-06-20
NZ289432A (en) 1998-05-27
TR199500778A1 (tr) 1996-10-21
NO970051D0 (no) 1997-01-07
PL179972B1 (pl) 2000-11-30
CA2194564C (en) 1997-12-16
SI9500220A (en) 1996-02-29
IL114525A0 (en) 1995-11-27
MX9700374A (es) 1997-04-30
RU2161965C2 (ru) 2001-01-20
ATE206931T1 (de) 2001-11-15
MY114389A (en) 2002-10-31
AU2927595A (en) 1996-02-09
CZ285204B6 (cs) 1999-06-16
HK1010691A1 (en) 1999-06-25
JPH09511751A (ja) 1997-11-25
HRP950397A2 (en) 1997-10-31
KR970704472A (ko) 1997-09-06
HU9700082D0 (en) 1997-02-28
BR9508253A (pt) 1997-12-23
HU222352B1 (hu) 2003-06-28
KR100212942B1 (ko) 1999-08-02
SK282159B6 (sk) 2001-11-06
EE9700009A (et) 1997-08-15
US5453425A (en) 1995-09-26
CA2194564A1 (en) 1996-01-25

Similar Documents

Publication Publication Date Title
BG63070B1 (bg) Лекарствени форми на рисперидон във воден разтвор
EP1057828A2 (en) Trovafloxacin oral suspensions
US7273870B2 (en) Stabilized difloxacin injectable solution
AU2017317523B2 (en) Pharmaceutical solution of Asenapine for sublingual or buccal use
JP4607761B2 (ja) 溶液医薬組成物
JP4892264B2 (ja) リスペリドン水性液剤
WO2013062497A1 (en) Liquid pharmaceutical formulations
JP4922657B2 (ja) リスペリドン経口用液剤
MXPA06014386A (es) Solucion acuosa de risperidona para administracion oral.
EP0662828A1 (en) Trimethoprim oral liquid
ES2323286T3 (es) Composiciones farmaceuticas de risperidona en disolucion acuosa.